Louis Tamayo's most recent trade in Lexeo Therapeutics Inc. was a trade of 12,000 Common Stock done . Disclosure was reported to the exchange on June 29, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics Inc | Louis Tamayo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2026 | 12,000 | 101,665 | - | 0 | Common Stock | |
| Lexeo Therapeutics Inc | Louis Tamayo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.49 per share. | 29 Jun 2026 | 4,641 | 97,024 | - | 4.5 | 20,838 | Common Stock |
| Lexeo Therapeutics Inc | Louis Tamayo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2026 | 226,665 | 226,665 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc | Louis Tamayo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2026 | 44,665 | 89,665 | - | 0 | Common Stock | |
| Lexeo Therapeutics Inc | Louis Tamayo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 280,000 | 280,000 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc | Louis Tamayo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 45,000 | 45,000 | - | 0 | Common Stock |